Table 3.
KOOS and EQ5D 1 and 5 years after ACLR
| Total | A | B | p value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Median (25th–75th percentile) | Mean ± SD | n | Median (25th–75th percentile) | Mean ± SD | n | Median (25th–75th percentile) | Mean ± SD | ||
| KOOS | ||||||||||
| Symptoms 1 y | 112 | 89 (79–89) | 85.7 ± 15.1 | 77 | 89 (77–96) | 85.3 ± 13.5 | 35 | 96 (82–100) | 86.6 ± 18.3 | n.s |
| Symptoms 5 y | 86 | 86 (68–93) | 81.3 ± 16.1 | 64 | 89 (68–93) | 82.4 ± 16.1 | 43 | 82 (68–93) | 79.7 ± 16.0 | n.s |
| Pain 1 y | 112 | 97 (89–100) | 92.5 ± 10.2 | 77 | 97 (88–100) | 92.4 ± 10.0 | 35 | 97 (89–100) | 92.7 ± 10.6 | n.s |
| Pain 5 y | 107 | 94(83–100) | 88.5 ± 14.3 | 64 | 94 (89–100) | 88.9 ± 16.5 | 43 | 89 (81–97) | 87.9 ± 10.1 | n.s |
| Adl 1 y | 112 | 100 (100–100) | 97.1 ± 7.5 | 77 | 100 (99–100) | 96.9 ± 7.7 | 35 | 100 (99–100) | 97.5 ± 7.2 | n.s |
| Adl 5 y | 107 | 99 (94–100) | 94.7 ± 11.8 | 64 | 100 (97–100) | 94.4 ± 14.4 | 43 | 99 (93–100) | 95.2 ± 6.3 | n.s |
| Sport/play 1 y | 112 | 90 (90–95) | 82.7 ± 20.3 | 77 | 90 (70–100) | 81.5 ± 22.6 | 35 | 85 (75–100) | 85.3 ± 13.8 | n.s |
| Sport/play 5 y | 107 | 80 (80–95) | 76.0 ± 24.7 | 64 | 85 (75–95) | 77.7 ± 26.5 | 43 | 75 (55–95) | 73.5 ± 21.6 | n.s |
| QoL 1 y | 112 | 75 (63–94) | 73.2 ± 23.2 | 77 | 81 (63–94) | 75.0 ± 22.1 | 35 | 75 (50–94) | 69.3 ± 25.3 | n.s |
| QoL 5 y | 107 | 75 (50–88) | 67.4 ± 26.0 | 64 | 75 (53–92) | 69.4 ± 27.0 | 43 | 63 (50–88) | 64.4 ± 24.5 | n.s |
| EQ-5D | ||||||||||
| EQ-5D index 1 y | 107 | 1 (1–1) | 0.9 ± 0.8 | 74 | 1 (0.8–1) | 0.9 ± 0.1 | 33 | 1 (0.8–1) | 0.9 ± 0.1 | n.s |
| EQ-5D index 5 y | 107 | 0.8 (0.8–1) | 0.9 ± 0.2 | 64 | 1 (0.8–1) | 0.9 ± 0.2 | 43 | 0.8 (0.7–1) | 0.9 ± 0.1 | n.s |
| EQ-5D VAS 1 y | 102 | 91 (80–99) | 87.7 ± 14.1 | 72 | 95 (81–100) | 89.4 ± 12.8 | 30 | 88 (80–96) | 83.6 ± 16.4 | n.s |
| EQ-5D VAS 5 y | 106 | 83.3 (70–94 | 78.2 ± 20.7 | 63 | 89 (74–95) | 79.3 ± 23.3 | 43 | 79 (70–87) | 76.6 ± 16.4 | n.s |
KOOS and EQ-5D presented for 1 and 5 years (y) after ACLR